.jpg)
Jonah Sacha, Ph.D.
Photo Credit: OHSU/Christine Torres Hicks
Scientific Frontline: Extended "At a Glance" Summary: Triple-Dose HIV Regimen for Newborns
The Core Concept: A one-time, three-part therapeutic regimen administered within 72 hours of birth that demonstrates the potential to permanently clear HIV infection in exposed newborns.
Key Distinction/Mechanism: Unlike standard treatments that only suppress the virus, this approach combines three distinct mechanisms to achieve clearance: antiretroviral therapy minimizes active viral replication, neutralizing antibodies corral circulating virus in the bloodstream, and the monoclonal antibody leronlimab blocks residual HIV from entering immune cells by sealing off the CCR5 surface receptor.
Major Frameworks/Components:
- Antiretroviral Therapy (ART): Standard treatment utilized to halt and minimize active viral replication.
- Broadly Neutralizing Antibodies: Immune proteins deployed to capture and reduce the volume of virus circulating within the blood supply.
- CCR5 Blockade: Application of leronlimab, an experimental monoclonal antibody, to inhibit HIV from accessing the CCR5 surface protein on immune cells.
- Critical Window of Efficacy: Treatment requires administration within a strict three-day (72-hour) window following initial viral exposure.





.png)


.jpeg)

.jpg)
.jpg)

